osimertinib
astrazeneca
['lung', 'osimertinib', 'tagrisso', 'adaura', 'astrazeneca']
astrazeneca presents reports p-iii trial (adaura) results of tagrisso (osimertinib) for early-stage egfr-mutated lung cancer at asco 2023 #clinicaltrials 
Real-time summarized News in 3 shots from pharma, biotech, medtech, digital health and life sciences industry readable in 60 seconds